MYC pathway activation in triple-negative breast cancer is synthetic lethal with CDK inhibition

Estrogen, progesterone, and HER2 receptor-negative triple-negative breast cancers encompass the most clinically challenging subtype for which targeted therapeutics are lacking. We find that triple-negative tumors exhibit elevated MYC expression, as well as altered expression of MYC regulatory genes,...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Glavni autori: Horiuchi, Dai, Kusdra, Leonard, Huskey, Noelle E., Chandriani, Sanjay, Lenburg, Marc E., Gonzalez-Angulo, Ana Maria, Creasman, Katelyn J., Bazarov, Alexey V., Smyth, James W., Davis, Sarah E., Yaswen, Paul, Mills, Gordon B., Esserman, Laura J., Goga, Andrei
Format: Artigo
Jezik:Inglês
Izdano: The Rockefeller University Press 2012
Teme:
Article
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3328367/
https://ncbi.nlm.nih.gov/pubmed/22430491
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1084/jem.20111512
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items